1

Your cart is empty.



Celebrating 23 YEARS of Regulatory Excellence!
Go with the Most-Trusted Regulations & Guidelines Books on the Market.


Now Taking Orders for Our April 1, 2025 Books!        ALSO Check Out our Books with the ICH E6(R3) GUIDELINE FOR GOOD CLINICAL PRACTICE       See our BOOKSTORE Drop-Down Menu for included titles

Book 16:  2025 Preambles to Good Clinical Practice Regulations

Book 16: 2025 Preambles to Good Clinical Practice Regulations

$ 28.95

Return to Previous Page

A great companion to Book 1, this spiral-bound, 8-1/2" x 11" book is a compilation of preambles to the GCP regulations, 21CFR parts 11, 50, 54, 56, 312 and 314. 

A preamble is the explanatory text that precedes a new or revised regulation when it is published by the federal government.  Preambles provide important background information on a regulation such as:

• The reason(s) for the regulation or change in in the regulation
• The FDA's intent and interpretation of the regulation
• Industry's comments on the proposed regulation
• Reasons for modification of the regulation from its proposed form
   to its final form

Who Uses this Book and How?

Anyone who wants a better understanding of the Good Clinical Practice Regulations.

What's the Price?
• 1-249 copies:  $28.95             • 250-499 copies:  $27.95
• 500-749 copies: $26.95          • 750+ copies:  $25.95

Custom Cover Prices*?
• 1-24 copies:  unavailable             • 25-100 copies:  $2.00/book
• 100-249 copies: $1.00/book        • 250+ copies:  No charge

* Based on quantities of a single book title

• Preamble to 21 CFR Part 11
• Electronic Records/Signatures (62 FR 13429, March 20, 1997)

• Preambles to 21 CFR Parts 50 and 56
• Informed Consent (46, FR 8942, January 27, 1981)
• Standards for Institutional Review Boards for Clinical
   Investigations (46 FR 8958, January 27, 1981)
• Clinical Investigations Which May Be Reviewed Through Expedited
   Review Procedure Set Forth in FDA Regulations (46 FR 8980,
   January 27, 1981)
• Informed Consent; Standards for Institutional Review Boards for
   Clinical Investigations; Proposed Rule (53, FR 45678, November
   1988)
• Informed Consent; Standards for Institutional Review Boards for
   Clinical Investigations; Final Rule (56 FR 28025, June 18, 1991)
• Informed Consent; Proposed Rule (60 FR 49085,
   September 21, 1995)
• Informed Consent; Proposed Rule (60 FR 66530,
   December 22, 1995)
• Informed Consent, Part II; Final Rule (61 FR 51498,
   October 2, 1996)
• Informed Consent Verification; Final Rule (61 FR 57277,
   November 5, 1996)
• Categories of Research That May Be Reviewed by the Institutional
   Review Board (IRB) Through an Expedited Review Procedure
   (63 FR 60353, November 9, 1998)
• Additional protections for children (66 FR 20589, April 24, 2001)

• Preamble to 21 CFR Parts 54
•  Financial Disclosure by a Clinical Investigator (63 FR 72171,
   December 31, 1998)


• Preambles to 21 CFR Parts 312 and 314
• Proposed New Drug, Antibiotic, and Biologic Drug Product
   Regulations (48 FR 26720, June 9, 1983)
• New Drug and Antibiotic Regulations (50 FR 7452,
   February 22, 1985)
• New Drug, Antibiotic, and Biologic Drug Product Regulations
   (52 FR 8798, March 19, 1987)
• Investigational New Drug Applications and New Drug
   Applications; Proposed Rule (60 FR 46794, September 8, 1995)
• Disqualification of a Clinical Investigator; Proposed Rule
   (61 FR 6177, February 16, 1996)
• Disqualification of a Clinical Investigator; Final Rule (62 FR 46875,
   September 5, 1997)
• Expedited Safety Reporting Requirements for Human Drug and
   Biological Products (62 FR 52237, October 7, 1997)
• Investigational New Drug Applications and New Drug Applications;
   Final Rule (63 FR 6854, February 11, 1998)
• Clinical Hold for products intended for life threatening conditions
   (65 FR 34963, June 1, 2000)

• Expanded Access to Investigational Drugs for Treatment Use
   (74 FR 40900, August 13, 2009)

Click here to see an enlarged pdf cover